Archives
Intraperitoneal mRNA-LNP Programming of CAR Macrophages in C
2026-07-14
Intraperitoneal mRNA-LNP Programming of CAR Macrophages in Cancer
Study Background and Research Question
Peritoneal metastasis remains a formidable obstacle in the clinical management of advanced solid tumors. Traditional interventions, such as cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, provide only limited benefit for select patient subsets. Immunotherapeutic strategies, including checkpoint inhibition, have not yet overcome the immunosuppressive nature of the peritoneal tumor microenvironment (TME), which often leads to immune evasion and disease progression. Notably, peritoneal ascites fluid is enriched with immune cells, with macrophages forming a substantial fraction, making them attractive candidates for cell-based immunotherapeutic engineering. The central research question addressed by Gu et al. (Nature Communications, 2025) is whether intraperitoneal delivery of mRNA lipid nanoparticles (mRNA-LNPs) can enable in situ programming of chimeric antigen receptor (CAR) macrophages that remodel the TME and enhance antitumor immunity in solid tumor metastases.Key Innovation from the Reference Study
The primary innovation in this work lies in the development and systematic evaluation of a macrophage-targeted mRNA-LNP platform for in vivo programming of CAR-expressing macrophages. Unlike prior approaches that rely on ex vivo modification and reinfusion, this strategy enables direct, local programming of endogenous or adoptively transferred macrophages within the peritoneal cavity. Critically, the authors designed and compared 36 distinct CAR constructs, focusing on the impact of intracellular domains (ICDs) on macrophage activation and antitumor function. Among the tested constructs, CAR-Ms incorporating CD3ζ and TLR4 ICDs demonstrated superior immunostimulatory potential, driving both innate and adaptive immune responses. This approach facilitates not only targeted tumor cell recognition but also re-education of the immunosuppressive TME, a key barrier in metastatic solid tumor immunotherapy.Methods and Experimental Design Insights
The study integrates several advanced methodologies:- Development of macrophage-targeted mRNA-LNPs for selective in vivo delivery and CAR expression.
- Systematic screening of 36 CAR-M formats, varying extracellular recognition and intracellular signaling domains.
- Single-cell RNA sequencing (scRNA-seq) to map cellular phenotypes and transcriptional changes in the TME post-CAR-M programming.
- Functional assessment of CAR-Ms for tumor cytotoxicity, phenotype, and synergy with PD-1/L1 checkpoint blockade.
- In vivo tumor models of peritoneal metastasis to evaluate therapeutic efficacy and immune remodeling.
Protocol Parameters
- mRNA-LNP formulation: Tailored for macrophage uptake; specific lipid ratios and encapsulation efficiency optimized for in vivo delivery to the peritoneal cavity.
- CAR design: 36 constructs tested; optimal configuration combined CD3ζ and TLR4 ICDs, validated by functional and transcriptomic assays.
- Intraperitoneal administration: Delivered directly to the peritoneal cavity to maximize local programming and minimize systemic exposure.
- Bioluminescence monitoring: Employs firefly luciferase substrate and D-Luciferin sodium salt for sensitive, ATP-dependent imaging of tumor and immune cell dynamics.
- Checkpoint inhibitor co-treatment: Anti-PD-1 or anti-PD-L1 administered to test combinatorial efficacy with programmed CAR-Ms.
Core Findings and Why They Matter
The study revealed several critical insights:- Macrophage-targeted mRNA-LNPs can effectively program CAR expression in situ, yielding functional CAR-Ms within the peritoneal TME (reference).
- CAR-Ms with CD3ζ/TLR4 ICDs maintain a proinflammatory phenotype, upregulate MHC class I and PD-L1, and robustly activate both innate and adaptive immunity, including expansion of TCF1+PD-1+ progenitor-exhausted CD8+ T cells (Tpex).
- Combining CAR-M programming with PD-1/L1 blockade produces synergistic antitumor effects, suggesting potential for improved clinical response in otherwise refractory peritoneal metastasis models.
- Single-cell transcriptomics confirmed extensive reshaping of the TME, with attenuation of immunosuppressive cell subsets and enhancement of effector immune populations.
Comparison with Existing Internal Articles
Several internal reviews contextualize and extend the relevance of the reference study's workflows:- Programming CAR Macrophages via mRNA-LNP for Solid Tumor Immunotherapy offers a comprehensive overview of the same Nature Communications study, emphasizing the systematic design and immunotherapeutic impact of mRNA-LNP-engineered CAR-Ms.
- D-Luciferin Sodium Salt: Enabling Precision Bioluminescence in Next-Gen CAR Macrophage Studies reviews how D-Luciferin sodium salt underpins high-sensitivity, ATP-dependent bioluminescence imaging workflows, which are critical for real-time, non-invasive monitoring of CAR-M activity and tumor metabolism.
- D-Luciferin Sodium Salt: Next-Gen Bioluminescent Imaging further explores the role of firefly luciferase substrates in oncology and immunotherapy research workflows, with emphasis on the advantages for metabolic and functional cell imaging.
Limitations and Transferability
While the intraperitoneal mRNA-LNP programming platform demonstrates robust preclinical efficacy, several limitations are worth noting:- The approach is currently validated in murine models, with human translation requiring further optimization of nanoparticle formulations, targeting specificity, and safety profiles.
- Long-term persistence and functional stability of in situ programmed CAR-Ms remain to be determined in clinical settings.
- Potential off-target effects and immune-related adverse events, particularly with combinatorial checkpoint blockade, warrant careful evaluation.
- Extrapolation to other metastatic settings or non-peritoneal tumors will require adaptation of delivery routes and microenvironmental considerations.